Journal article icon

Journal article

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS

Abstract:
Objective: Capecitabine is an oral 5-fluorouracil (5-FU) pro-drug commonly used to treat colorectal carcinoma and other tumours. About 35% of patients experience dose-limiting toxicity. The few proven genetic biomarkers of 5-FU toxicity are rare variants and polymorphisms, respectively, at candidate loci dihydropyrimidine dehydrogenase (DPYD) and thymidylate synthase (TYMS).

Actions


Access Document


Publisher copy:
10.1136/gutjnl-2013-306571

Authors


Rosmarin, D More by this author
Pagnamenta, A More by this author
Expand authors...
Publisher:
BMJ Publishing Group
Journal:
Gut
Volume:
64
Issue:
1
Pages:
111-120
Publication date:
2015
DOI:
EISSN:
1468-3288
ISSN:
0017-5749
URN:
uuid:a0056c2c-a222-4fe0-b5a9-d34f346f3697
Source identifiers:
502608
Local pid:
pubs:502608
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP